Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
2,447 results
  • Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy. [Journal Article]
    Thorac Cardiovasc Surg. 2020 Jun 27 [Online ahead of print]Schlachtenberger G, Deppe AC, … Wahlers TCW
  • CONCLUSIONS:  Dual antiplatelet therapy is associated with higher rates of major bleeding. Further studies should examine the difference in the prevalence of major bleeding complications in the different dual antiplatelet therapy regimes in patients requiring urgent surgery.
  • Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. [Review]
    J Clin Med. 2020 Jun 23; 9(6)Numasawa Y, Sawano M, … Kohsaka S
  • Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has become the standard of care, particularly in patients with acute coronary syndrome (ACS). Current clinical guidelines recommend novel P2Y12 inhibitors (e.g., prasugrel or ticagrelor) in addition to aspirin based on the results of representative randomized controlled trials conducted predominantly in Western countries. T…
  • Treatment with flow diverter stent during pregnancy. [Journal Article]
    Neuroradiology. 2020 Jun 22 [Online ahead of print]Pop R, Cebula H, … Beaujeux R
  • Intracranial aneurysms are rarely diagnosed during pregnancy. If treatment is necessary, surgery was traditionally preferred over embolization in case of ongoing pregnancy, due to concerns regarding foetal radiation exposure. We present a case of 21 mm unruptured carotid-ophthalmic aneurysm diagnosed during pregnancy and treated with flow diversion. Foetal radiation dose was estimated between 1 a…
  • How do type of preoperative P2Y12 receptor inhibitor and withdrawal time affect bleeding. [Journal Article]
    Ann Thorac Surg. 2020 Jun 18 [Online ahead of print]Voetsch A, Pregartner G, … Mahla E
  • CONCLUSIONS: Exposure to prasugrel and ticagrelor within 24 hours before CABG increases both calculated blood loss and BARC-4 bleeding as compared to clopidogrel. Although a >48 hours discontinuation substantially reduced calculated blood loss and BARC-4 bleeding across all P2Y12 receptor inhibitors, our single center data further support strict adherence to the 2017 guidelines whenever justified by stable hemodynamics and non-jeopardized myocardium.
  • Antiplatelet Therapy And Percutaneous Coronary Interventions. [Journal Article]
    Curr Cardiol Rev. 2020 Jun 15 [Online ahead of print]Davanzo RH, Alarcon AF, … Rodriguez GM
  • Dual antiplatelet therapy is one of the cornerstones of modern percutaneous coronary interventions. The development of new therapeutic agents has significantly reduced ischemic events at the risk of increased bleeding complications. Therefore, efforts are currently focused on optimizing therapeutic algorithms to obtain the greatest anti-thrombotic benefit associated with the lowest risk of bleedi…
  • Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS. [Journal Article]
    Platelets. 2020 Jun 05 [Online ahead of print]Biesinger BS, Gasecka A, … Siller-Matula JM
  • Inflammation leads to atherosclerosis and acute coronary syndromes (ACS). We performed a prospective, observational study to assess association between the concentrations of inflammatory markers (high sensitivity C-reactive protein, hsCRP; high sensitivity interleukin6, hsIL-6; soluble CD40 ligand, sCD40 L) and platelet reactivity in 338 patients with ACS treated with ticagrelor and prasugrel. We…
  • Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. [Journal Article]
    BMC Cardiovasc Disord. 2020 Jun 03; 20(1):268.Al-Rubaish AM, Al-Muhanna FA, … Al-Ali AK
  • CONCLUSIONS: The risk of stent thrombosis in PCI patients is usually reduced by dual anti-platelet therapy, comprising aspirin and a P2Y12 inhibitor, such as clopidogrel. However, clopidogrel requires activation by the cytochrome P450 enzyme, CYP2C19. Approximately 20% of the population are unable to activate clopidogrel as they possess the CYP2C19*2 loss-of function (LoF) allele. The primary goal of this trial is to study the benefits of treating only those patients that cannot activate clopidogrel with an alternative that has shown to be a more effective platelet inhibitor and does not require bioactivation by the cytochrome P450 enzyme. We expect an improvement in net clinical benefit outcome in the active arm patients, thus supporting pharmacogenetic testing in PCI patients post STEMI.
  • StatPearls: Prasugrel [BOOK]
    . StatPearls Publishing: Treasure Island (FL) Sampat Parth J. PJ SUNY Upstate Medical University Wadhwa Roopma R South Carolina Department of Mental Health BOOK
  • Prasugrel is an antiplatelet agent in the thienopyridine group.[1] Prasugrel is used to decrease the rate of cardiovascular events in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention. Prasugrel has approval for medical management of patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI), and patients with ST-elevation myoc…
  • Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development. [Journal Article]
    Expert Opin Investig Drugs. 2020 May 12 [Online ahead of print]Milluzzo RP, Franchina GA, … Angiolillo DJ
  • Introduction: Platelet P2Y12 inhibitors have a key role in reducing thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) and those with acute coronary syndrome (ACS). Clopidogrel, prasugrel and ticagrelor are widely prescribed oral P2Y12 receptor antagonists, but numerous clinical and pharmacological factors can lead to impaired gastrointestinal absorption resu…
  • Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review. [Review]
    J Thorac Dis. 2020 Apr; 12(4):1656-1664.Biondi-Zoccai G, Antonazzo B, … Nudi F
  • Percutaneous coronary intervention has become a mainstay in the management of coronary artery disease. While initially advanced age was considered a relative contraindication to invasive management of coronary artery disease, current cardiovascular practice stands solidly on an early invasive approach for elderly patients, typically based on radial access and drug-eluting stent implantation. Sinc…
  • Prasugrel in the treatment of acute coronary syndrome. [Journal Article]
    Future Cardiol. 2020 May 11 [Online ahead of print]Spartalis M, Tzatzaki E, … Voudris V
  • Dual antiplatelet therapy is the mainstay therapy in patients with acute coronary syndrome. The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events. The newer P2Y12 inhibitors (prasugrel and ticagrelor) have better efficacy than clopidogrel. Prasugrel provides greater inhibi…
  • Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. [Journal Article]
    J Thromb Thrombolysis. 2020 Apr 25 [Online ahead of print]Cirillo P, Taglialatela V, … Cimmino G
  • Platelets aggregation leading to thrombosis plays a pivotal role in the pathophysiology of acute coronary syndrome (ACS) and of stent thrombosis. Antiplatelet therapy with aspirin plus an ADP-receptor inhibitor (ticagrerol, prasugrel or clopidogrel) is recommended to reduce the risk of other platelet-mediated events. Clopidogrel is recommended in patients with Chronic Coronary Syndromes (CCS) or …
New Search Next